‘Vertex stock traded as high as $37.85 in afternoon trading before trimming its gains to close up a little more than 5%.
Before the market’s open, the company said that preliminary Phase II results showed that none of the 12 patients in the trial who used VX-950 in combination with two other leading hepatitis C drugs showed any tangible sign of the virus in their bloodstream after 28 days.
Vertex had tested VX-950 with the drugs pegylated interferon alfa-2a and ribavirin, current standards in treating the life-threatening liver disease. The 28-day study was not designed to measure how long the immune response could be sustained, according to the company.
Vertex plans to unveil full results from the study at medical conference later this year.’
Read more at Vertex Pharma jumps on hepatitis C results
February 8th, 2006 by Pharmaceutical Observer | No Comments »